Aurora Spine Receives “Notice of Allowance” for Patent: DEXA Technology™ The World’s First Patient-Matched Interbody Implant Technology to Enable Improved Spine Surgery

CARLSBAD, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) today announced it has received “Notice of Allowance” for its patent from the United States Patent and Trademark Office (USPTO) for Patient-Matched Interbody Implant Technology.

This patent will be utilized to create spinal implants that match the patient’s specific bone density based on a DEXA Scan/T-score allowing for the best bone fusion treatment and most favorable outcome based on that patient’s bone density.

Traditionally, medical devices for spinal procedures are ‘one size fits all’ and assumes that every patient’s bone density is similar. Not all patients have the same bone density, but most implants have a significantly higher density and are more rigid than bone found in spine joints.  Aurora Spine patient matched implants will be bone density specific and may be used on patients with osteoporotic bone.

“Today, we are extremely excited about this patent that will be issued. Aurora Spine is once again positioned to reshape the market through patent focused innovation and address the next advancement in spine surgery – DEXA Interbody Technology,”  said Trent Northcutt, President and Chief Executive Officer of Aurora Spine. “This patent will allow for the development of implants that will match a patient’s bone density. We have placed a lot of effort and time into validating the bone match technology and are prepared to immediately commence testing of this new innovation.”

Laszlo Garamszegi, Chief Technology Officer, added, “We believe the DEXA technology creates opportunities for patients with osteoporosis to receive fusion treatment similar to patients with healthy bone density. We are very excited about the ongoing steps toward launching this patient-matched technology.”

About Aurora Spine

Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Information” in Aurora Spine’s final prospectus (collectively, “forward-looking information”). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine’s securities about important factors that could cause Aurora Spine’s actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.

Contact:

Aurora Spine Corporation

Trent Northcutt
President and Chief Executive Officer
(760) 424-2004

Chad Clouse
Chief Financial Officer
(760) 424-2004
www.aurora-spine.com

Adam Lowensteiner
LYTHAM PARTNERS, LLC
Phoenix | New York
Telephone: 646-829-9700
arosf@lythampartners.com